Glaukos has ended its patent infringement lawsuit against Ivantis’ Hydrus Microstent, accepting a $60 million payment and 10% royalities until April 2025.
Glaukos began legal proceedings in April 2018, alleging that Ivantis’ Hydrus Microstent bears similarities to its minimally invasive glaucoma surgery (MIGS) iStent technology. The settlement is accompanied by an agreement that there will be no further legal action regarding Hydrus and iStent.
“Glaukos has invested considerable time and resources to develop novel technologies that have pioneered an entirely new treatment category for glaucoma surgeons and their patients,” said Thomas Burns, Glaukos president and chief executive officer. “We remain confident in the strength of our robust intellectual property portfolio and believe this settlement allows us to focus our full attention and resources on executing our long-term growth strategy by bringing transformative new technologies to the market for the benefit of patients worldwide.”